FDA Self-Apposing® Stent Continues to Demonstrate Low Mortality at One Year in APPOSITION III Trial

PRINCETON, N.J. & PARIS--(BUSINESS WIRE)--STENTYS (FR0010949404 – STNT), a medical technology company commercializing in Europe the world’s first and only Self-Apposing® stent to treat acute myocardial infarction (AMI), today reports its third-quarter and 9-month revenues through 30 September 2012.